Download Files:
LLL12
$120 – $580
Products Details
Product Description
– LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth[1].
Web ID
– HY-19536
Storage Temperature
– 4°C (Powder, protect from light)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C14H9NO5S
References
– [1]Zhang R, et al. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells. Oncol Rep. 2020 Sep;44(3):1224-1232.|[2]Onimoe GI, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012 Jun;30(3):916-26.
CAS Number
– 1260247-42-4
Molecular Weight
– 303.29
Compound Purity
– 98.00
SMILES
– O=S(C(C=CC=C1C(C2=C3C=CC=C2O)=O)=C1C3=O)(N)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 100 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– STAT
Isoform
– STAT3
Pathway
– JAK/STAT Signaling;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
